HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target

Benzinga · 09/27 15:00
HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.